Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 12/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496217 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19509409 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL18954971 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL10457794 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19880310 | 1.00 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19502688 | 0.93 | TAS1R3 (0.46) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19502422 | 0.93 | TAS1R3 (0.46) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL25496214 | 0.92 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL23350694 | 0.92 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1STING1PDE3B | |
| SCHEMBL19491657 | 0.88 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1STING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | Janssen Biopharma, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-3386536-A2 | COMPOSITION OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | Opi Vi- IP Holdco LLC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2331558-B1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
| WO-2017100305-A2 | COMPOSITION OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC (US) | 2017-06-15 | — | — | WO | disclosed |
| US-9273086-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2331558-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | Agilent Technologies, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010034024-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20070172925-A1 | Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound | NIPPON SHINYAKU CO., LTD. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1710249-A1 | RIBONUCLEIC ACID COMPOUND AND METHOD OF LIQUID-PHASE SYNTHESIS OF OLIGONUCLEIC ACID COMPOUND | Nippon Shinyaku Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | KDM4E 3375/4885TAS1R3 1381/4885TAS1R1 1315/4885 |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | KDM4E 1268/4885TAS1R3 4231/4885TAS1R1 4165/4885 |
| US-20070172925-A1 | Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound | RNASEH1, NSUN2, POLR2H | KDM4E 3505/4885TAS1R3 4120/4885TAS1R1 3419/4885 |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | STING1, BID, VIP | KDM4E 4168/4885TAS1R3 490/4885TAS1R1 691/4885 |
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | NT5C3B, PNP, NME1 | KDM4E 1564/4885TAS1R3 2186/4885TAS1R1 2652/4885 |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, RNGTT, RNMT | KDM4E 2664/4885TAS1R3 4261/4885TAS1R1 4266/4885 |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | RNGTT, RNMT, NSUN2 | KDM4E 3173/4885TAS1R3 3959/4885TAS1R1 3872/4885 |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | KDM4E 4665/4885TAS1R3 1087/4885TAS1R1 1391/4885 |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | NSUN2, RNGTT, RNMT | KDM4E 2664/4885TAS1R3 4261/4885TAS1R1 4266/4885 |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | NSUN2, SNRPB2, RNGTT | KDM4E 1268/4885TAS1R3 4231/4885TAS1R1 4165/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | KDM4E 3200/4885TAS1R3 3654/4885TAS1R1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.